Affymetrix (AFFX), Lineagen to Collaborate on Next-Gen FirstStepDx for DD, ASD Evaluation
Tweet
Share
E-mailGet Alerts AFFX Hot Sheet
Join SI Premium – FREE
Affymetrix, Inc. (Nasdaq: AFFX) and Lineagen, Inc., have signed an agreement to incorporate Affymetrix' GeneChip technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD).
The new FirstStepDx offering is anticipated to be available by mid-2012 and will feature a proprietary microarray-based assay incorporating novel genetic markers from recently concluded studies of more than 10,000 individuals.
Under the terms of the agreement, Lineagen has exclusive rights to develop a chromosomal microarray assay based on Affymetrix' GeneChip technology platform as part of the Powered by Affymetrix™ program. In this program, Affymetrix licenses its technology to companies developing microarray products in a broad range of test applications, including diagnostics.
Financial terms of the agreement were not disclosed.
The new FirstStepDx offering is anticipated to be available by mid-2012 and will feature a proprietary microarray-based assay incorporating novel genetic markers from recently concluded studies of more than 10,000 individuals.
Under the terms of the agreement, Lineagen has exclusive rights to develop a chromosomal microarray assay based on Affymetrix' GeneChip technology platform as part of the Powered by Affymetrix™ program. In this program, Affymetrix licenses its technology to companies developing microarray products in a broad range of test applications, including diagnostics.
Financial terms of the agreement were not disclosed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Gray Media closes $750M note offering to refinance higher-rate debt
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
